Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease - Aliskiren and sympathetic activity

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-005401-22-NL

Enrollment

Registered

2007-10-19

Start date

2009-02-20

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension and chronic kidney disease

Interventions

Product Name: Aliskiren (Rasilez) Product Code: ATC-code: C09XA02 Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable CKD and hypertension: i.e. using antihypertensive drugs and/or blood pressure >145/90mmHg when off medication. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Patients on renal replacement therapy - Diabetes mellitus - Pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD. ;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function - Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren	—

Measure

Time frame

Main Objective: The primary objective is to investigate the effect on MSNA by Aliskiren in hypertensive patients with CKD. We hypothesize that there will be a (substantial) decrease in MSNA as result of chronic treatment (6 weeks) of Aliskiren. ;Secondary Objective: Secondary objective is to assess whether MSNA normalizes after chronic treatment (6 weeks) of Aliskiren in hypertensive patients with CKD. Furthermore, we will study the effect of Aliskiren on blood pressure, heart rate, kidney function and PRA in hypertensive patients with CKD. ;Primary end point(s): Primary endpoint: the effect of Aliskiren on MSNA Secondary parameters: Effect of aliskiren on blood pressure, heart rate, PRA and kidney function - Comparison of the effect on MSNA after treatment with aliskiren with the effects on ACEi and ARB as comared to the previous studies and assessment whether normalization of MSNA is obtained after treatment with aliskiren

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026